A quantitative structure-activity relationship study of novel, potent, orally active, selective VEGFR-2 and PDGFRα tyrosine kinase inhibitors: Derivatives of N-Phenyl-N′-{4-(4-quinolyloxy phenyl}urea as antitumor agents

Journal of Enzyme Inhibition and Medicinal Chemistry

Volumn 23, Issue 2, 2008, Pages 168-173

  Sharma, B K ^a   Sharma, S K ^a   Singh, P ^a   Sharma, Susheela ^b  

^a S K Government College   (India)

^b Sobhasaria Engineering College Sikar   (India)

Author keywords

N Phenyl N 4 (4 quinolyloxy)phenyl urea derivatives; PDGF receptor; Physicochemical properties; QSAR; Tyrosine kinase inhibitors; VEGF 2 receptor

Indexed keywords

ANTINEOPLASTIC AGENT; FUNCTIONAL GROUP; N PHENYL N' [4 (4 QUINOLYLOXY)PHENYL]UREA DERIVATIVE; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 2 INHIBITOR;

ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG ACTIVITY; DRUG DESIGN; DRUG POTENCY; DRUG SELECTIVITY; DRUG SYNTHESIS; ENZYME CHEMISTRY; ENZYME INHIBITION; HUMAN; HUMAN CELL; HYDROGEN BOND; HYDROPHOBICITY; IC 50; MOLECULAR MECHANICS; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; STEREOSPECIFICITY;

ADMINISTRATION, ORAL; ANTINEOPLASTIC AGENTS; MOLECULAR STRUCTURE; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; QUINOLINES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 40949085595     PISSN: 14756366     EISSN: 14756374     Source Type: Journal    
DOI: 10.1080/14756360701450301     Document Type: Article

References (36)

1. Folkman, J. (1972) Anti-angiogenesis: New concept for therapy of solid tumors. Ann Surg, 175, pp. 409-416.
2. Liotta, LA, Kleinerman, J. and Saidel, GM (1974) Quantitative relationships of intravascular tumor cells, tumor vessels and pulmonary metastases following tumor implantation, Cancer Res, 34, pp. 997-1004.
3. Eckhardt, SG (1999) Angiogenesis inhibitors as cancer therapy. Hosp Pract, pp. 63-84.
4. Bergers, G., Javaherian, K., Lo, K-M, Folkman, J. and Hanahan, D. (1999) Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science, 284, pp. 808-812.
5. Fan, T-PD, Jaggar, R. and Bicknell, R. (1995) Controlling the vasculature: Angiogenesis, antiangiogenesis and vascular targeting of gene therapy. Trends Pharmacol Sci, 16, pp. 57-66.
6. Kim, KJ, Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, HS and Ferrara, N. (1993) Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature, 362, pp. 841-844.
7. Kolch, W., Martiny-Baron, G., Kieser, A. and Marme, D. (1995) Regulation of the expression of VEGF/VPS and its receptors: Role in tumor angiogenesis. Breast Cancer Res Treat, 36, pp. 139-155.
8. Leenders, WPJ (1998) Targetting VEGF in anti-angiogenic and anti-tumor therapy: Where are we now?. Int J Exp Pathol, 79, pp. 339-346.
9. Strawn, LM, McMahon, G., App, H., Schreck, R., Kuchler, WR, Longhi, MP, Hui, TH, Tang, C., Levitzki, A., Gazit, A., Chen, I., Keri, G., Orfi, L., Risau, W., Flamme, I., Ullirich, A., Hirth, KP and Shawver, LK (1996) Fik-1 as a target for tumor growth inhibition. Cancer Res, 56, pp. 3540-3545.
10. Millauer, B., Longhi, MP, Plate, KH, Shawver, LK, Risau, W., Ullrich, A. and Strawn, LM (1996) Dominant-negative inhibition of Fik-1 suppresses the growth of many tumor types in vivo. Cancer Res, 56, pp. 1615-1620.
11. Kim, KJ, Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, HS and Ferara, N. (1993) Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature, 362, pp. 841-844.
12. Prewett, M., Huber, J., Li, Y., Santiago, A., O'Connor, W., King, K., Overholser, J., Hopper, A., Pytowski, B., Witte, L., Bohlen, P. and Hicklin, DJ (1999) Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res, 59, pp. 5209-5218.
13. Dumas, J. (2001) Protein kinase inhibitors: Emerging pharmacophores 1997-2000. Exp Opin Ther Pat, 11, pp. 405-429.
14. Connell, RD and Beebe, JS (2001) Patent focus on cancer chemotherapeutics. II Angiogenesis agents: April 2000-September 2000. Exp Opin Ther Pat, 11, pp. 77-114.
15. Sun, L., Tran, N., Tang, F., App, H., Hirth, P., McMahon, G. and Tang, C. (1998) Synthesis and biological evaluations of 3-substituted Indolin-2-ones: A novel class of tyrosine kinase inhibitors that exhibit selectivity toward particular receptor tyrosine kinases. J Med Chem, 41, pp. 2588-2603.
16. Fong, TAT, Shawver, LK, Sun, L., Tang, C., App, H., Powell, TJ, Kim, YH, Schreck, R., Wang, X., Risau, W., Ullrich, A., Hirth, KP and McMahon, G. (1999) SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Fik-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization and growth of multiple tumor types. Cancer Res, 59, pp. 99-106.
17. Sun, L., Tran, N., Liang, C., Tang, F., Rice, A., Schreck, R., Waltz, K., Shawver, LK, McMahon, G. and Tang, C. (1999) Design, synthesis and evaluation of substituted 3-[(3- or 4-carboxyethyl-pyrrol-2-yl)methyidenyl]indolin-2-ones as inhibitors of VEGF, FGF and PDGF receptor tyrosine kinases. J Med Chem, 42, pp. 5120-5130.
18. Laird, AD, Vajkoczy, P., Shawver, LK, Thurnher, A., Liang, C., Mohammadi, M., Schlessinger, J., Ullrich, A., Hubbard, SR, Blake, RA, Fong, TAT, Strawn, LM, Sun, L., Tang, C., Hawtin, R., Tang, F., Shenoy, N., Hirth, KP, McMahon, G. and Cherrington, JM (2000) SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Cancer Res, 60, pp. 4152-4160.
19. Hennequin, LF, Thomas, AP, Johnstone, CE, Stokes, ESE, Ple, P., Lohmann, J-JM, Ogilvie, DJ, Dukes, M., Wedge, SR, Curwen, JO, Kendrew, J. and Lambert-van-der-Brempt, C. (1999) Design and structure-activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors. J Med Chem, 42, pp. 5369-5389.
20. Wedge, SR, Ogilvie, DJ, Dukes, M., Kendrew, J., Curwen, JO, Hennequin, LF, Thomas, AP, Stokes, ESE, Curry, B., Richmond, GH and Wadsworth, PF (2000) ZD4190: An orally active inhibitor of vascular endothelial growth factor signaling with broadspectrum antitumor efficacy. Cancer Res, 60, pp. 970-975.
21. Hennequin, LF, Stokes, ESE, Thomas, AP, Johnstone, C., Ple, P., Ogilvie, DJ, Dukes, M., Wedge, SR, Kendrew, J. and Curwen, JO (2002) Novel 4-anilinoquinazolines with C-7 basic side chains: Design and structure-activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors. J Med Chem, 45, pp. 1300-1312.
22. Wedge, SR, Ogilvie, DJ, Dukes, M., Kendrew, J., Chester, R., Jackson, JA, Boffey, SJ, Valentine, PJ, Curwen, JO, Musgrove, HL, Graham, GA, Hughes, GD, Thomas, AP, Stokes, ESE, Curry, B., Richmond, GHP, Wadsworth, PF, Bigley, AL and Hennequin, LF (2002) ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res, 62, pp. 4645-4655.
23. Bold, G., Altmann, K-H, Frei, J., Lang, M., Manley, PW, Traxler, P., Wietfeld, B., Bruggen, J., Buchdunger, E., Cozens, R., Ferrari, S., Furet, P., Hofmann, F., Martiny-Baron, G., Mestan, J., Rosel, J., Sills, M., Stover, D., Acemoglu, F., Boss, E., Emmenegger, R., Lasser, L., Masso, E., Roth, R., Schlachter, C., Vetterli, W., Wyss, D. and Wood, JM (2000) New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor driven angiogenesis. J Med Chem, 43, pp. 2310-2323.
24. Wood, JM, Bold, G., Buchdunger, E., Cozens, R., Ferrari, S., Frei, Hofmann, F., Mestan, J., Mett, H., O'Reilly, T., Persohn, E., Rosel, J., Schnell, C., Stover, D., Theuer, A., Towbin, H., Wenger, F., Woods-Cook, K., Menrad, A., Siemeister, G., Schirner, M., Thierauch, K-H, Schneider, MR, Drevs, J., Martiny-Baron, G., Totzke, F. and Marme, D. (2000) PTK787/ ZK222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res, 60, pp. 2178-2189.
25. Fernand, NH and Hurwitz, HI (2003) Inhibition of vascular endothelial growth factor in the treatment of colorectal cancer. Semin Oncol, pp. 39-50.
26. Yang, JC, Haworth, L., Sherry, RM, Hwu, P., Schwartzentruber, JD, Topalian, SL, Steinberg, SM, Chen, HX and Rosenberg, SA (2003) A randomized trial of bevacizumab, an antivascular endothelial growth factor antibody, for metastatic renal cancer. N Eng J Med, 349, pp. 427-434.
27. Kubo, K., Shimizu, T., Ohyama, S., Murooka, H., Iwai, A., Nakamura, K., Hasegawa, K., Kobayashi, Y., Takahashi, N., Takahashi, K., Kato, S., Izawa, T. and Isoe, T. (2005) Novel potent orally active selective VEGFR-2 tyrosine kinase inhibitors: Synthesis, structure-activity relationships and antitumor activities of N-Phenyl-N′-{4-(4-quinolyloxy)phenyl}ureas. J Med Chem, 48, pp. 1359-1366.
28. Kubo, K., Shimizu, T., Ohyama, S., Murooka, H., Nishitoba, T., Kato, S., Kobayashi, Y., Yagi, M., Isoe, T., Nakamura, K., Osawa, T. and Izawa, T. (1997) A novel series of 4-phenoxyquinolines:POtent and highly selective inhibitors of PDGF receptor autophosphorylation. Bioorg Med Chem Lett, 23, pp. 22935-22940.
29. Yagi, M., Kato, S., Kobayashi, Y., Kubo, K., Ohyama, S., Shimizu, T., Nishitoba, T., Isoe, T., Nakamura, K., Ohashi, H., Kobayashi, N., Iinuma, N., Osawa, T., Onose, R. and Osada, H. (1997) Selective inhibition of platelet-derived growth factor (PDGF) receptor autophosphory- lation and PDGF-mediated cellular events by quinoline derivatives. Exp Cell Res, 234, pp. 285-292.
30. Yagi, M., Kato, S., Kobayashi, Y., Kobayashi, N., Iinuma, N., Nakamura, K., Kubo, K., Ohyama, S., Murooka, H., Shimizu, T., Nishitoba, T., Osawa, T. and Nagano, N. (1998) Beneficial effects of a novel inhibition of platelet-derived growth factor receptor autophosphorylation in the rat with mesangial proliferative glomerulonephritis. Gen Pharmacol, 31, pp. 765-773.
31. Kubo, K., Ohyama, S., Shimizu, T., Takami, A., Murooka, H., Nishitoba, T., Kato, S., Yagi, M., Kobayashi, Y., Iinuma, N., Isoe, T., Nakamura, K., Iijima, H., Osawa, T. and Izawa, T. (2003) Synthesis and structure-activity relationship for new series of 4-phenoxyquinoline derivatives as specific inhibitors of platelet-derived growth factor receptor tyrosine kinase. Bioorg Med Chem, 11, pp. 5117-5133.
32. Hansch, C., Leo, A., Unger, SH, Kim, KH, Nikaitani, D. and Lien, EJ (1973) Aromatic substituents constants for structure-activity correlations. J Med Chem, 16, pp. 1207-1216.
33. Unger, SH and Hansch, C. (1976) Quantitative models of steric effects. Prog Phys Org Chem, 12, pp. 91-118.
34. Hansh, C. and Leo, A. (1979) Substituents constants for correlation analysis in chemistry and biology, John Wiley, New York
35. Wold, S. (1991) Validation of QSAR's. Quant Struct-Act Relat, 10, pp. 191-193.
36. Singh, P., Kumar Rajesh and Sharma, BK (2003) Quantitative structure-activity relationship study of 5-iodo- and diaryl-analogues of tubercidin: Inhibitors of adenosine kinase. J Enz Inhib Med Chem, 18, pp. 395-402.